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The t(9;22) translocation that results in the formation ofthe Philadelphia chromosome (Ph) causes expressionof the BCR-ABL tyrosine kinase fusion protein.
Depending on the translocation breakpoint within the BCR
gene, a protein of 210 kDa (termed BCR-ABL p210) or 185
kDa (termed BCR-ABL p185) can be expressed (Figure 1).
Expression of p210 is the molecular hallmark of chronic
myelogenous leukemia, whereas in Ph+ acute lymphoblastic
leukemia (Ph+ ALL) expression of either p210 or p185 can be
found. In contrast to its proto-oncogenic counterpart c-ABL,
BCR-ABL displays constitutive tyrosine kinase activity.1 The
ATP-competitive BCR-ABL tyrosine kinase inhibitor ima-
tinib leads to durable remissions in the majority of patients
with chronic myelogenous leukemia in the chronic phase
and converted chronic myelogenous leukemia to a chronic
disease. Imatinib also improved the previously devastating
outcome in Ph+ ALL patients. However, the occurrence of
imatinib resistance mutations in the ABL kinase domain
became clinically problematic and led to the development of
nilotinib and dasatinib, both also ATP-competitive inhibitors,
which target most imatinib-resistant BCR-ABL mutations.2
Still, short-lived responses in advanced phase chronic myel-
ogenous leukemia and Ph+ ALL, resistance caused by the
T315I mutation, compound mutations (two or more muta-
tions in the same clone) and foreseeable problems with long-
term tolerability of all three BCR-ABL inhibitors remain chal-
lenging problems.3
The unsuspected identification of an allosteric site on the
kinase domain with a location distinct from the catalytic
cleft, to which imatinib and its successors bind, offered an
alternative possibility to target imatinib-resistant BCR-ABL.
Seminal work revealed molecular structures of autoinhibited
c-ABL and showed intramolecular binding of the N-terminal
myristate moiety of c-ABL to a deep hydrophobic pocket in
the kinase domain.4,5 Myristoylation is a co-translational
covalent modification of the N-terminus of approximately
100 different human proteins, including c-ABL. Myristate
binding causes a 90° bending of the α-I helix in the kinase
domain that is required for the assembly of the catalytically
inactive (autoinhibited) conformation of c-ABL.4-6 Removal of
the myristate or blocking its binding pocket led to the disas-
sembly of the autoinhibited c-ABL conformation by unbend-
ing the α-I helix and resulted in a dramatic increase of kinase
activity.6 In the BCR-ABL fusion protein, the very N-terminus
of ABL (including the myristoylation site) is missing because
of the translocation event (Figure 1), whereas the myristate
pocket in the kinase domain is preserved (and supposedly
not occupied). This observation implied that chemical com-
pounds that bind to the myristate pocket could re-establish
some of the c-ABL autoinhibitory constraints that are lost in
BCR-ABL (Figure 2).5 As a consequence BCR-ABL activity
would be allosterically inhibited. Furthermore, such com-
pounds should be able to inhibit imatinib resistance muta-
tions, as an alternative site is being targeted.
How to find such allosteric inhibitors targeting
the myristate pocket? 
Nathanael Gray and his team pursued a clever approach by
using a high-throughput cell-based screen identifying numer-
ous compounds that inhibited the growth of Ba/F3 cells
expressing BCR-ABL p210, but not of parental Ba/F3 cells,
thereby enabling the identification of BCR-ABL-selective
compounds.7 Structural inspection of the screening hits and
discrimination of compounds belonging to known ATP-com-
petitive inhibitor scaffolds resulted in the identification of a
lead scaffold, of which one derivative, termed GNF-2, was
chosen for further follow-up. Binding experiments with
recombinant ABL showed that GNF-2 did indeed act as a
non-ATP competitive (allosteric) inhibitor and that its binding
to the ABL kinase domain could be blocked by previously
described mutants in the myristate binding pocket which pre-
vented myristate binding.5,7 Some BCR-ABL forms carrying
imatinib resistance mutations were sensitive to GNF-2,
whereas others, including the T315I mutation that is resistant
to imatinib, nilotinib and dasatinib, were also resistant to
GNF-2.7 This was a puzzling observation as none of the ima-
tinib resistance mutations is in proximity to the myristate
binding pocket. Evidence of 'gain-of-function' properties,
such as increased kinase activity or oncogenic transformation,
has been obtained for some imatinib resistance mutations and
in particular for the T315I mutation.8-10 It has been argued that
some BCR-ABL kinase domain mutants causing imatinib
resistance are able to stabilize a more active conformation of
BCR-ABL to which imatinib binds less well. As the proposed
mechanism of action of GNF-2 is to re-establish an inactive
(autoinhibited) conformation of BCR-ABL, the observed
cross-resistance to GNF-2 would fit this model (Figure 2).
Recent elegant structural work, combining evidence from
crystallography, nuclear magnetic resonance and hydrogen-
exchange mass spectrometry experiments confirmed the pro-
posed binding mode and mechanism of action of GNF-2 (and
its close derivative GNF-5).11 Furthermore, a combination of
nilotinib and GNF-5 was shown to prolong survival of mice
in a BCR-ABL T315I xenograft model, whereas each drug
alone had no effect.11 This work and additional observations
from in vitro drug combination studies12,13 provided convincing
evidence that the combined application of ATP-competitive
and allosteric BCR-ABL inhibitors can overcome resistance to
either agent alone. Nevertheless, the efficacy of GNF-2 on pri-
mary human Ph+ leukemia cells has not been demonstrated. 
In this issue of Haematologica, Mian et al. explored the effi-
cacy and the clinical feasibility of allosteric inhibition in the
treatment of Ph+ ALL.14 The authors compared the sensitivity
of BCR-ABL p210 and BCR-ABL p185 to GNF-2 inhibition, as
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it was not known whether p185 is inhibited by GNF-2
and, if so, how strong the inhibition is in comparison to
that of p210. The authors used primary cells from Ph+ ALL
patients expressing either p185 or p210, as well as Ba/F3
cells that were retrovirally transduced to express p185 or
p210 and other established ALL cell lines. Consistently,
the sensitivity of p210 to GNF-2 was 3-5 fold higher than
that of p185 when assaying inhibition of cell proliferation,
BCR-ABL autophosphorylation and phosphorylation of
the canonical BCR-ABL substrate CrkL. This differential
sensitivity was also preserved when imatinib-resistant
kinase domain point mutants in the P-loop of p185 and
p210 were assayed. In contrast, both p210 and p185 carry-
ing the T315I mutation were insensitive to GNF-2. The
molecular basis for the observed differential sensitivity is
unclear, as both BCR-ABL isoforms carry the identical
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Figure 1. Schematic
domain representa-




ABL exons is repre-
sented as a gray verti-
cal line. The exons of
the BCR and ABL1
genes that are includ-
ed in the fusion pro-
teins and the number
of amino acids of the
full-length proteins
are indicated.
Figure 2. Schematic representation of the mechanism of action of BCR-ABL/c-ABL myristate pocket binders. The SH3, SH2 and kinase
domains are shown in yellow, green and blue, respectively. The BCR-part and the C-terminal last exon region downstream of the ABL kinase
domain is shown without further details on domains or sequence motifs. The myristoyl group that is attached to the N-terminus of c-ABL
binds to a deep hydrophobic pocket in the kinase domain and induces bending of the C-terminal αI'-helix (shown in dark red). BCR-ABL is
not myristoylated, but retains the myristate pocket. GNF-2 binds to the myristate pocket (left panel), bends the αI'-helix (as myristate binding
does) and induces a c-ABL-like autoinhibited conformation of BCR-ABL that has reduced kinase activity. In contrast, binding of DPH to the
myristate pocket (right panel) is not compatible with the inactive conformation and leads to activation of ABL kinase activity by un-bending
the αI'-helix and disruption of autoinhibitory constraints. Next to the schematic representations, a blow-up shows the myristate pocket from
the crystal structures of the ABL kinase domain alone and in complex with myristate,19 GNF-211 or DPH15.
ABL-part (Figure 1). A possible explanation could be that
p185 can less readily conduct the conformational changes
that commence with GNF-2 binding (Figure 2).
Alternatively, differences in the downstream signaling net-
works of the two BCR-ABL isoforms might be responsi-
ble. The presented data not only further establishes
allosteric inhibition as a possible alternative targeted
approach for the treatment of Ph+ ALL, but also underlines
the notion that the BCR-ABL breakpoint needs to be accu-
rately defined in order to choose the optimal treatment
regimen. Given the observed lower GNF-2 sensitivity of
p185 one may predict that patients expressing p210
respond better than patients expressing p185 in possible
future clinical studies involving GNF-2.
It is interesting to note that another class of compounds
that target the ABL myristoyl pocket was recently identi-
fied in a high-throughput screen. In contrast to GNF-2, the
compound DPH, potently activated (rather than inhibited)
c-ABL kinase activity.15 DPH was able to displace a myris-
toylated peptide that corresponded in sequence to the N-
terminus of c-ABL from the myristoyl pocket.
Importantly, DPH is not able to induce the bent conforma-
tion of the α-I helix that is seen in the autoinhibited ABL
structures upon binding of myristate and induced by bind-
ing of GNF-2 (Figure 2). Therefore, although GNF-2 and
DPH both bind to the myristate pocket, GNF-2 inhibits
BCR-ABL activity, whereas DPH activates c-ABL activity.
These differences are due to the ability of GNF-2 to enable
and of DPH to prevent bending of the α-I helix in the
kinase domain. The identification of DPH and other c-ABL
activators targeting the myristoyl pocket16 provides very
valuable tools for studying the physiological functions of
endogenous c-ABL.
In conclusion, during the past 10 years we have wit-
nessed the ascent of first- (imatinib), second- (nilotinib and
dasatinib) and several third-generation ATP-competitive
BCR-ABL inhibitors. Together with the identification of
allosteric inhibitors of BCR-ABL targeting the myristate
pocket, the N-terminal coiled-coil oligomerization
domain,17 or the SH2-kinase domain interaction,18 we are
provided with a large tool-kit to study the regulation of
wild-type and mutated BCR-ABL. This will enable us to
make rational decisions for the best possible combination
of two or more of these highly potent targeted agents and
to assess their efficacy in pre-clinical models and ultimate-
ly in patients with Ph+ leukemias.
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